In this randomized trial in men with mCRPC, we aim to determine the efficacy of a response-based flexible dosing schedule of177Lu-PSMA-617 RLT administered up to 12 treatment cycles compared to the current standard of care.Methods:This is an investigator-initiated prospective phase 2, open-...
studies and retrospective analyses reported that the phar- macokinetics and dosimetry of [177Lu]Lu-PSMA-I&T and [177Lu]Lu-PSMA-617 are similar [2]. Likewise, protocols of the respective phase 3 trials that evaluate [177Lu]Lu- PSMA-617 (NCT04689828) and [177Lu]Lu-PSMA-...
Methods: This is an investigator initiated prospective phase 2, open-label, randomized, controlled, parallel group, single-center trial. The aim is to assess the 2-year survival rate in mCRPC patients treated with a flexible dosing schedule of 177Lu-PSMA therapy up to 12 cycles in comparison ...
2e17058#Background:The phase III VISION trial demonstrated that177Lu-PSMA-617 (PSMA-RLT) prolonged overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC). Common side effects of PSMA-RLT include xerostomia, bone pain, and myelosuppression. The objective of this ...
In contrast, changes in tumor uptake on interim PSMA-PET imaging during 177Lu-PSMA radioligand therapy were not associated with survival outcome.doi:10.1016/j.mednuc.2025.01.164L. DjailebCHUGA, clinique universitaire de médecine nucléaire - CUMN, GrenobleF. Andrea...
[177Lu]Lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: Prior and concomitant treatment subgroup analyses of the VISION trial.doi:10.1200/JCO.2022.40.16_suppl.5001115001#Background:In the phase 3 VISION trial, targeted radioligand therapy with lutetium (177Lu) vipivot...
[(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): A single-centre, single-arm, phase 2 study. Lancet Oncol. 2018, 19, 825–833. [Google Scholar] [CrossRef] Violet, J.; Sandhu, S.; Iravani, A.; Ferdinandus, J.;...
3.2. Patients Treated with 177Lu-PSMA-617 More than 850 patients with progressive mCRPC have been treated with 177Lu-PSMA-617 in the context of three randomized phase 2 and 3 clinical trials [23,24,27]. While the majority of patients in these trials had an Eastern Cooperative Oncology Group...